Original Research

Tolerability and Cosmetic Acceptability of Liquor Carbonis Distillate (Coal Tar) Solution 15% as Topical Therapy for Plaque Psoriasis

Author and Disclosure Information

Although generally recognized as an effective therapy for psoriasis, coal tar therapy lost appeal in modern clinical practice due to poor patient acceptability of its aesthetic properties. A new liquor carbonis distillate (LCD) solution 15% (equivalent to coal tar 2.3%) that uses an evaporative and transparent vehicle, fragrance, and a dab-on applicator was developed. Cosmetic acceptability of the LCD solution was compared to calcipotriene cream 0.005% during a randomized, active-controlled, investigator-blinded clinical trial. Participants with moderate plaque psoriasis applied LCD solution or calcipotriene cream twice daily to body lesions for 12 weeks and then were followed for 6 additional weeks without treatment. Participants completed a cosmetic acceptability survey about their medications after starting therapy. Mean ratings for aesthetic and product performance attributes were high in both groups; however, more participants treated with LCD solution versus calcipotriene cream rated their product as more convenient and beneficial compared to prior psoriasis therapies. Ratings of the scent, staining, drying time, and dab-on applicator for the LCD solution were favorable. Participant experience with LCD solution in this study suggests that it is a cosmetically acceptable psoriasis treatment that is comparable to calcipotriene cream.


 

Recommended Reading

Trauma Linked to Development of Arthritis in Psoriasis Patients
MDedge Dermatology
AAD: Etanercept Safety for Children with Psoriasis Holds Up in Extension Study
MDedge Dermatology
Report, Summit Address the State of Autoimmune Diseases
MDedge Dermatology
AAD: Ustekinumab Enhances Sexual Function for Psoriasis Patients
MDedge Dermatology
AAD: Psoriasis Increases Risk of Psychiatric Disorders in Kids
MDedge Dermatology
ACR: Antimalarial Tx May Slow Cutaneous LE Progression to SLE
MDedge Dermatology
Vaginal Tablets Useful for Oral Candidiasis in Sjögren's Syndrome
MDedge Dermatology
AAD: Methotrexate May Drive Infection Risk in RA
MDedge Dermatology
ACR: Epstein-Barr Virus May Be New Therapeutic Target in SLE
MDedge Dermatology
Making Strides in Juvenile Dermatomyositis
MDedge Dermatology